To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
Description: Number of Patients with Systemic Adverse EventsMeasure: Total Numer of Systemic Adverse Events Time: 2 years
Description: Number of Patients with Other Adverse EventsMeasure: Total Number of Other Adverse Events (>5%) Time: 2 years
There is one SNP
Subjects will be treated with "combination therapy" of IVT Fovista® and IVT anti-VEGF therapy every month for the first 5 months (Day 1, Months 1,2,3,4), followed by Q12W (every 12 weeks) administration (Months 7,10, 13,16, 19 and 22), for a total of 24 months. --- Q12W ---